Abstract
Fungal infections afflict an increasing number of patients due to increases in susceptible immunosuppressed populations such as those receiving chemotherapy, transplant conditioning or infections such as HIV. Poor responses to available therapy have prompted searches for novel drug targets, but screens can be difficult as expression of these targets often relies on specific inducing conditions present within the mammalian host. Cryptococcus is a yeast-like basidiomycete fungus capable of causing fatal cryptococcocis in both immunocompetent and immunocompromised individuals, and is currently the fourth cause of infectious death in regions of Sub-Sahara Africa, excluding HIV. A key virulence factor of Cryptococcus is a cell-wall laccase, which produces melanin in the presence of exogenous catecholamines. Screening melanin-deficient strains of the fungus is facile and has identified cellular processes critical for virulence including copper homeostasis and autophagy. As demonstrated here through the analysis of laccase regulatory networks of Cryptococcus, genetic analysis targeting virulence-associated regulatory pathways can lead to the discovery of promising novel drug candidates against fungal species.
Keywords: AIDS, biological markers, clinical markers, Cryptococcus, drug design, laccase, regulation, review.
Current Enzyme Inhibition
Title:Laccase Regulators in Anti-fungal Drug Discovery: Dark Lessons from the AIDS-related Pathogen, Cryptococcus
Volume: 9 Issue: 2
Author(s): Jennifer Rabjohns and Peter R. Williamson
Affiliation:
Keywords: AIDS, biological markers, clinical markers, Cryptococcus, drug design, laccase, regulation, review.
Abstract: Fungal infections afflict an increasing number of patients due to increases in susceptible immunosuppressed populations such as those receiving chemotherapy, transplant conditioning or infections such as HIV. Poor responses to available therapy have prompted searches for novel drug targets, but screens can be difficult as expression of these targets often relies on specific inducing conditions present within the mammalian host. Cryptococcus is a yeast-like basidiomycete fungus capable of causing fatal cryptococcocis in both immunocompetent and immunocompromised individuals, and is currently the fourth cause of infectious death in regions of Sub-Sahara Africa, excluding HIV. A key virulence factor of Cryptococcus is a cell-wall laccase, which produces melanin in the presence of exogenous catecholamines. Screening melanin-deficient strains of the fungus is facile and has identified cellular processes critical for virulence including copper homeostasis and autophagy. As demonstrated here through the analysis of laccase regulatory networks of Cryptococcus, genetic analysis targeting virulence-associated regulatory pathways can lead to the discovery of promising novel drug candidates against fungal species.
Export Options
About this article
Cite this article as:
Rabjohns Jennifer and Williamson R. Peter, Laccase Regulators in Anti-fungal Drug Discovery: Dark Lessons from the AIDS-related Pathogen, Cryptococcus, Current Enzyme Inhibition 2013; 9 (2) . https://dx.doi.org/10.2174/1573408011309020006
DOI https://dx.doi.org/10.2174/1573408011309020006 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Stem Cell Transplant and Idiotypic Vaccination for B-Cell Malignancies
Current Topics in Medicinal Chemistry Statins as the Controlling Agents for Non-Hodgkin's Lymphomas via Increasing the Casein Kinase 2 Interacting Protein-1: A Hypothesis
Current Drug Discovery Technologies Toxicological Aspects of Carbon Nanotubes, Fullerenes and Graphenes
Current Pharmaceutical Design Implications of Somatic Mutations in the AML1/RUNX1 Gene in Myelodysplastic Syndrome (MDS): Future Molecular Therapeutic Directions for MDS
Current Cancer Drug Targets Potential Roles of Eosinophils in Cancer Therapy: Epidemiological Studies, Experimental Models, and Clinical Pathology
Recent Patents on Anti-Cancer Drug Discovery Therapeutic Potential of Janus Kinase 3 (JAK3) Inhibitors
Current Pharmaceutical Design MicroRNA Dysregulation in Esophageal Neoplasia: The Biological Rationale for Novel Therapeutic Options
Current Pharmaceutical Design Artificial Blood: A Futuristic Dimension of Modern Day Transfusion Sciences
Cardiovascular & Hematological Agents in Medicinal Chemistry Synthesis and Applications of Hydrogels in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Current and Potential Anticancer Drugs Targeting Members of the UHRF1 Complex Including Epigenetic Modifiers
Recent Patents on Anti-Cancer Drug Discovery Hypomethylation of Urokinase (uPA) Promoter in Breast and Prostate Cancer: Prognostic and Therapeutic Implications
Current Cancer Drug Targets 5-Aryl-1,3,4-Thiadiazole-Based Hydroxamic Acids as Histone Deacetylase Inhibitors and Antitumor Agents: Synthesis, Bioevaluation and Docking Study
Medicinal Chemistry Biosafety Considerations Using Gamma-Retroviral Vectors in Gene Therapy
Current Gene Therapy Editorial (Thematic Issue: “miRNA and Cancer; Computational and Experimental Approaches”)
Current Pharmaceutical Biotechnology Induction of Regulatory T Cells by Dendritic Cells through Indoleamine 2,3- dioxygenase: A Potent Mechanism of Acquired Peripheral Tolerance
Current Medicinal Chemistry Tyrosine Kinase Mutations in Human Cancer
Current Molecular Medicine AKT: A Potential Target for Thyroid Cancer Therapy
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Lymphoproliferative Disorders and Chemokines
Current Drug Targets Amphiphilic Cyclodextrin Derivatives for Targeted Drug Delivery to Tumors
Current Topics in Medicinal Chemistry The Potential of PI3K/AKT/mTOR Signaling as a Druggable Target for Endometrial and Ovarian Carcinomas
Current Drug Targets